A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2016; you can also visit the original URL.
The file type is
Current treatment regimens for patients with breast cancer should consider molecular genetic type of tumor. To identify aggressive tumors in medical practice assess the proliferation marker Ki-67 and apoptosis marker p53, but there are no data about its prognostic value in patients BLBC living in the south-east ofUkraine. For low-grade tumors, which include BLBC, characterized by a high degree of mitotic activity. In patients with BLBC in more than 50 % cases there was detected infiltratingdoi:10.11603/mcch.2410-681x.2016.v0.i3.6936 fatcat:kxsfs7srafg6ndmm664foaesuy